key: cord-0954913-klwkdrgx authors: Moein, Shima T.; Hashemian, Seyed Mohammad Reza; Mansourafshar, Babak; Khorram‐Tousi, Ali; Tabarsi, Payam; Doty, Richard L. title: Reply to: Psychophysical olfactory testing in COVID‐19: Is smell function really impaired in nearly all patients? date: 2020-06-04 journal: Int Forum Allergy Rhinol DOI: 10.1002/alr.22638 sha: 9aa3ff8f910143a25a27477b9addd94d80751196 doc_id: 954913 cord_uid: klwkdrgx nan Mariño-Sánchez and colleagues have raised a number of issues regarding our recent COVID-19 olfactory paper. 1 In this paper we found that 59 of 60 COVID-19 patients exhibited at least some degree of smell loss, as measured by the validated Persian version of the 40-item University of Pennsylvania Smell Identification Test (UPSIT). However, only 25% were anosmic. A major concern of these authors is that "the UPSIT is commonly used in America. Nevertheless this test may not be adequate for Iranian population." They first support this concern by citing the findings of a study by Kamrava et al. 2 in which the American UPSIT was administered to Iranian subjects, with the result that a number of odorant items were found wanting. What they fail to consider or point out, despite the mention of this fact in our paper, is that we did not use the American UPSIT in this study. As clearly indicated in the paper, we modified and validated the 40-item Persian UPSIT on an Iranian population to take into account cultural factors. Moreover, they fail to note that we employed age-and sex-matched Iranian normal controls against which comparisons were made. They also seem unaware of the fact that the UPSIT is not only available in an American (i.e., North American) version, but has been culturally revised and translated into over 30 different languages for multiple cultures. It is noteworthy that a number of UPSIT odorants we used and validated in Iran performed well for us, but this was not the case for Kamrava et al. Of the 40 items, 29 are common between the two tests, and 11 odorants are different. We found much higher identification rates for 16 of the odorants common to the two papers. For example, onion had a 100% identification rate in our Iranian healthy subjects (which is evident universality of onion. The same was true for wintergreen, which reached a 93% identification rate in our study and only 43% in the Kamrava study. We speculate that the latter difference could be due to issues with translation (we employed the term Vicks in addition to Wintergreen, per se, to facilitate identification). It is important to note that in the Kamrava et al. study there was no significant difference between the familiarity ratings of the 16 odorants that reached the 70% identification level and those 24 that did not reach this criterion (p = 0.13). Interestingly, wintergreen received the highest average familiarity score even though the mean identification rate was low (43%). Leather had a very low familiarity score (of 40 odorants, only 5 were rated lower) yet achieved a 75% identification rate. Kamrava et al. mention that their data were based on "healthy adult volunteers" but fail to mention the age of their subjects. If they were older, this could have contributed to the lower test scores. 3 As shown in the Figure, Taherkhani test score is based on 24 items, reflecting an 89% correct response rate (21.41/24) and the Moein et al. COVID-19 test score is based on 40 items, resulting in a 52% correct response rate (20.98/40). Mariño-Sánchez et al. refer to the high rate of smell loss we observed as "alarming". It is noteworthy that a new publication in which the first author of this critique is a co-author found, using a rather crude intensity measure and common household odors, that 81% of those with confirmed COVID-19 demonstrated smell dysfunction. 5 Moreover, based on the cut-off for normality, the following is stated in this paper: "This is of course a conservative measure that will bias our estimates towards a potential lower prevalence given that there might be asymptomatic COVID-19 patients or individuals with olfactory dysfunction prior to the COVID-19 pandemic." Another point made by Mariño-Sánchez et al. is that, "Since the control group was "healthy" and not patients with similar symptoms but SARS-CoV-2 PCR negative, the frequency of loss of smell could also be due to viral (common cold) or post-viral infection." As we noted in our paper, the Iranian control group was tested outside the period of the first known COVID-19 case in Iran. It was never tested using PCR for SARS-CoV-2. The controls were vetted for any ongoing infections or disturbances that might otherwise preclude their participation and we clearly note in the manuscript that "none of the controls had influenza or common cold symptoms at the time of testing." In light of the above, the suggestion by Mariño-Sánchez and colleagues that "Moen et al. should re-analyze their data, using only odorants of UPSIT valid for Smell dysfunction: a biomarker for COVID-19 University of Pennsylvania Smell Identification on Iranian Population Smell identification ability: changes with age Iran Smell Identification Test (Iran-SIT): a Modified Version of the University of Pennsylvania Smell Identification Test (UPSIT) for Iranian Population Relationship between odor intensity estimates and COVID-19 prevalence prediction in a Swedish population This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.